Study of cardiovascular disease biomarkers among tobacco consumers, part 1: biomarkers of exposure

Leanne R Campbell, Buddy G Brown, Bobbette A Jones, Kristin M Marano, Michael F Borgerding, Leanne R Campbell, Buddy G Brown, Bobbette A Jones, Kristin M Marano, Michael F Borgerding

Abstract

A study was conducted to evaluate biomarkers of biological effect and physiological assessments related to cardiovascular disease (CVD) among adult male cigarette smokers (SMK), moist snuff consumers (MSC) and non-consumers of tobacco (NTC). Additionally, biomarkers of tobacco and tobacco smoke exposure (BoE) were measured in spot urines and are reported here. Except for the BoE to nicotine and NNK, BoE were generally greater in SMK compared with MSC, and BoE were generally not different in comparisons of MSC and NTC. Results demonstrated that MSC had lower systemic exposures to many harmful and potentially harmful constituents than SMK, which is consistent with epidemiological data that indicate a differential in CVD risk between these groups.

Keywords: CVD; Cigarettes; clinical study; harmful and potentially harmful constituents; moist snuff; spot urines.

References

    1. Adhikari B, Kahende J, Malarcher A, et al. Smoking-attributable mortality, years of potential life lost, and productivity losses – United States, 2000–2004. MMWR. 2008;57:1226–8.
    1. Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis. 2003;46:91–111.
    1. Byrd GD, Ogden MW. Liquid chromatographic/tandem mass spectrometric method for the determination of the tobacco-specific nitrosamine metabolite NNAL in smokers’ urine. J Mass Spectrom. 2003;38:98–107.
    1. Calapai G, Caputi AP, Mannucci C, et al. A cross-sectional investigation of biomarkers of risk after a decade of smoking. Inhal Toxicol. 2009;21:1138–43.
    1. Federal Trade Commission (FTC) FTC rescinds guidance from 1966 on statements concerning tar and nicotine yields. 2008 Available from: [Last accessed 7 Nov 2012]
    1. Food and Drug Administration (FDA) Guidance for industry: reporting harmful and potentially harmful constituents in tobacco products and tobacco smoke under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act. Draft guidance. 2012 Available from: [Last accessed 25 Mar 2014]
    1. Gillespie CD, Wigington C, Hong Y. Coronary heart disease and stroke deaths—United States, 2009. MMWR. 2013;62:157–60.
    1. Gregg EQ, Minet E, McEwan M. Urinary biomarkers of smokers' exposure to tobacco smoke constituents in tobacco products assessment: a fit for purpose approach. Biomarkers. 2013;18:467–86.
    1. Hansson J, Galanti MR, Hergens MP, et al. Use of snus and acute myocardial infarction: pooled analysis of eight prospective observational studies. Eur J Epidemiol. 2012;27:771–9.
    1. Hansson J, Galanti MR, Hergens MP, et al. Snus (Swedish smokeless tobacco) use and risk of stroke: pooled analyses of incidence and survival. J Int Med. 2014;276:87–95.
    1. Hatsukami DK, Benowitz NL, Rennard SI, et al. Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res. 2006;8:600–22.
    1. Heavner DL, Morgan WT, Sears SB, et al. Effect of creatinine and specific gravity normalization techniques on xenobiotic biomarkers in smokers’ spot and 24-h urines. J Pharm Biomed Anal. 2006;40:928–42.
    1. Hecht SS, Carmella SG, Edmonds A, et al. Exposure to nicotine and a tobacco-specific carcinogen increase with duration of use of smokeless tobacco. Tob Control. 2008;17:128–31.
    1. Hecht SS, Carmella SG, Murphy SE, et al. Similar exposure to a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers. Cancer Epidemiol Biomarkers Prev. 2007;16:1567–72.
    1. Henley SJ, Connell CJ, Richter P, et al. Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tob Control. 2007;16:22–8.
    1. Henley SJ, Thun MJ, Connell C, Calle EE. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States) Cancer Causes Control. 2005;16:347–58.
    1. Heudorf U, Angerer J. Urinary monohydroxylated phenanthrenes and hydroxypyrene – the effects of smoking habits and changes induced by smoking on monooxygenase-mediated metabolism. Int Arch Occup Environ Health. 2001;74:177–83.
    1. Institute of Medicine (IOM) Scientific standards for studies on modified risk tobacco products. Washington, DC: The National Academies Press; 2011.
    1. International Agency for Research on Cancer (IARC) Smokeless tobacco and some tobacco-specific N-nitrosamines. IARC monographs on the evaluation of carcinogenic risks to humans, volume 89. Lyon, France: World Health Organization; 2007.
    1. Jilma B, Dirnberger E, Löscher I, et al. Menstrual cycle-associated changes in blood levels of interleukin-6, alpha1 acid glycoprotein, and C-reactive protein. J Lab Clin Med. 1997;130:69–75.
    1. Lee PN, Hamling J. Systematic review of the relation between smokeless tobacco and cancer in Europe and North America. BMC Med. 2009;7:36.
    1. Lowe FJ, Gregg EO, McEwan M. Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers. Clin Chem Lab Med. 2009;47:311–20.
    1. Marano KM, Kathman SJ, Jones BA. Study of cardiovascular disease biomarkers among tobacco consumers, part 3: evaluation and comparison with the US National Health and Nutrition Examination Survey. Inhal Toxicol 2015
    1. Meger M, Meger-Kossien I, Schuler-Metz A, et al. Simultaneous determination of nicotine and eight nicotine metabolites in urine of smokers using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;778:251–61.
    1. Messner B, Bernhard D. Smoking and cardiovascular disease mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014;34:509–15.
    1. Nan HM, Kim H, Lim HS, et al. Effects of occupation, lifestyle and genetic polymorphisms of CYP1A1, CYP2E1, GSTM1 and GSTT1 on urinary 1-hydroxypyrene and 2-naphthol concentrations. Carcinogenesis. 2001;22:787–93.
    1. Naufal ZS, Marano KM, Kathman SJ, Wilson CL. Differential exposure biomarker levels among cigarette smokers and smokeless tobacco consumers in the National Health and Nutrition Examination Survey 1999-2008. Biomarkers. 2011;16:222–35.
    1. Nordskog BK, Brown BG, Marano KM. Study of cardiovascular disease biomarkers among tobacco consumers, part 2: biomarkers of biological effect. Inhal Toxicol 2015
    1. Nutt DJ, Phillips LD, Balfour D, et al. Estimating the harms of nicotine-containing products using the MCDA approach. Eur Addict Res. 2014;20:218–25.
    1. Piano MR, Benowitz NL, Fitzgerald GA, et al. Impact of smokeless tobacco products on cardiovascular disease: implications for policy, prevention, and treatment: a policy statement from the American Heart Association. Circulation. 2010;122:1520–44.
    1. Roethig HJ, Munjal S, Feng S, et al. Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers. Nicotine Tob Res. 2009;11:1216–25.
    1. Scherer G. Biomonitoring of inhaled complex mixtures – ambient air, diesel exhaust and cigarette smoke. Exp Toxicol Pathol. 2005;57:75–110.
    1. Stepanov I, Hecht SS. Tobacco-specific nitrosamines and their pyridine-N-glucuronides in the urine of smokers and smokeless tobacco users. Cancer Epidemiol Biomarkers Prev. 2005;14:885–91.
    1. Stratton K, Shetty P, Wallace R, Bondurant S. Clearing the smoke: the science base for tobacco harm reduction—executive summary. Tob Control. 2001;10:189–95.
    1. Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. J Am Med Assoc. 2000;284:706–12.
    1. US Department of Health and Human Services. (USDHHS) The health consequences of smoking: a report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
    1. US Department of Health and Human Services. (USDHHS) How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010.
    1. Vesper HW, Caudill SP, Osterloh JD, et al. Exposure of the U.S. population to acrylamide in the National Health and Nutrition Examination Survey 2003–2004. Environ Health Perspect. 2010;118:278–83.
    1. World Health Organization (WHO) Cardiovascular diseases (CVDs), Fact Sheet No. 317. 2013 Available from: [Last accessed 27 Mar 2014]
    1. Zeller M, Hatsukami D. Strategic Dialogue on Tobacco Harm Reduction Group The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US. Tob Control. 2009;18:324–32.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren